← Back to Search

Cryoablation

Ablation for Atrioventricular Node Reentrant Tachycardia (Cryo-FP Trial)

Phase < 1
Waitlist Available
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial will study a new, less risky ablation technique for a heart condition called atrioventricular nodal reentrant tachycardia.

Eligible Conditions
  • Atrioventricular Node Reentrant Tachycardia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Termination of AVNRT
Secondary study objectives
Cardiac tamponade
Freedom from recurrence
Incidence of AV block
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: AblationExperimental Treatment1 Intervention
Mapping and ablation of the retrograde fast pathway with cryotherapy
Group II: MappingActive Control1 Intervention
Standard treatment involving ablation of the slow pathway with cryotherapy

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
676 Previous Clinical Trials
416,623 Total Patients Enrolled
University of Western Ontario, CanadaOTHER
165 Previous Clinical Trials
319,288 Total Patients Enrolled
~3 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top